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ITF2357 (Givinostat) is a potent antineoplastic histone deacetylase inhibitor which is currently used 
in clinical trials for leukemias and myelomas and in the therapy for  systemic juvenile idiopathic 
arthritis. 
Here evidence is provided that ITF2357 reduces the viability of human melanoma SK-Mel28 cells 
thereby inducing cell death.  This compound was more efficacious than SAHA, another well known 
HDAC inhibitor belonging to the same class of hydroxamic acids. Moreover, we demonstrated for 
the first time that ITF2357 determines in SK-Mel28 cells a remarkable reduction in the level of 
oncogenic B-Raf, the product of the BRAF V600E mutated gene in melanoma. Western blot 
analysis showed that the decrease of oncogenic B-Raf induced by ITF2357 is dose and time 
dependent. This effect was accompanied with a decrease in the level of phosho-ERK confirming the 
blockage of the B-Raf mitogenic pathway.  
To potentiate the inhibition of this pathway, the MEK inhibitor UO126 was used in combination 
with ITF2357. The results indicated that this compound increases the effect of ITF2357 on cell 
death. Intriguingly, UO126 not only reduced ERK phosphorylation, as a confirmation of MEK 
inhibition, but also consistently reduced the level of B-Raf when combined with ITF2357.  
These preliminary results suggest that ITF2357, either alone or in combination with UO126,  can be 
considered a good candidate in melanoma targeted therapy and ongoing studies will further clarify 
the mechanism of oncogenic B-Raf inhibition. 
 
 
